Viewing Study NCT07432594

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2026-03-26 @ 3:19 PM
Ignite Modification Date: 2026-07-07 @ 7:37 PM
Study NCT ID: NCT07432594
Status: NOT_YET_RECRUITING
Last Update Posted: 2026-02-25
First Post: 2026-02-12
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None High-grade Serous Ovarian Cancer (HGSOC) View
None Fallopian Tube Cancers View
None Primary Peritoneal Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Neoadjuvant Chemotherapy View
None Interval Debulking Surgery View
None PD-1/CTLA-4 Bispecific Antibody View
None Aitua Combination Antibody View
None Nab-paclitaxel View
None Carboplatin View
None Immunotherapy View